A previous preclinical study showed that treatment with PARP inhibitors leads to cell cycle arrest and cell death in cells with a homologous recombination deficiency (HRD) [54,56,57]. The gene discussed is PARP1; the disease is hyperinsulinemic hypoglycemia, familial, 4.